Discovery Pre-Clinical Phase 1 Phase 2 Phase 3
Oral PTH Antagonist
Hypercalcemia

Oral PTH Antagonist


Parathyroid hormone (PTH) regulates calcium and phosphate homeostasis in bone and kidney through activation of its receptor, PTHR1. Our team hypothesizes that blocking PTH action via a PTH receptor antagonist may provide an improved therapeutic mechanism to treat patients with primary hyperparathyroidism (PHPT) as well as those with humoral hypercalcemia of malignancy (HHM).

For the Treatment of Primary Hyperparathyroidism (PHPT)


Primary hyperparathyroidism (PHPT) arises from a small, benign tumor on one or more of the parathyroid glands , which results in oversecretion of parathyroid hormone (PTH), leading to increased blood calcium levels (hypercalcemia). Some patients experience no symptoms, many can have surgery to remove the tumor and/or hyperactive gland(s), while some require managed with medical therapy. Symptomatic PHPT is characterized by skeletal, renal, gastrointestinal, and neurological manifestations with increased mortality.

For the Treatment of Humoral Hypercalcemia of Malignancy (HHM)


Humoral hypercalcemia of malignancy (HHM) is typically arises in patients with advanced-stage cancers. In cases of HHM, oversecretion of parathyroid hormone-related peptide (PTHrP) caused by the malignant tumor results in bone resorption and calcium reabsorption in the kidney, leading to hypercalcemia.

We have identified potent and orally available nonpeptide PTH antagonists that also exhibit good oral exposure in preclinical species, activity in preclinical models, and appropriate drug-like properties. Currently, we are evaluating a subset of potential candidate molecules via a battery of pharmacology and safety studies to identify the optimal one(s) suitable for evaluation in human clinical trials.